Blue Earth Diagnostics, a Bracco company, has signed a nonexclusive data-sharing agreement with Siemens Healthineers.
For its syngo.via platform, Siemens plans to evaluate anonymized clinical data and images from Blue Earth's Posluma (flotufolastat F-18) injection (formerly known as F-18 rhPSMA-7.3) phase III Lighthouse study, an open-label, prospective, phase III, multicenter, single-dose imaging study investigating the safety and diagnostic performance of Posluma PET imaging in men with newly diagnosed prostate cancer. The study enrolled 356 patients at clinical sites in the U.S. and Europe.
Siemens will utilize the Lighthouse data to improve its analytics and AI-based algorithms for prostate cancer image quantification and interpretation across its PET/CT imaging software, according to the vendor.
Blue Earth said it also plans to make analytical data from the phase III Spotlight trial of Posluma available in the future. That study was an open-label, prospective, phase III, multicenter, single-dose imaging study investigating the safety and efficacy of Posluma PET imaging in men with suspected prostate cancer recurrence. The study enrolled 391 patients at clinical sites in the U.S. and Europe.
